The present invention relates to the field of biological pharmacy, and discloses a fusion protein rLZ-8-HAS of ganoderma lucidum immunoregulatory protein and human serum albumin that is produced by using a genetic engineering technology, and a production method therefor and uses thereof. Compared with rLZ-8, the fusion protein prolongs an in-vivo half-life period and improves the biological activity, and can be used as drugs for treating leucopenia and tumors.